Deagreez/iStock via Getty Images Just over 4 months have passed since my last article, "Is Novo Nordisk Immune to President Trump's Drug Price Plans." What was it about? In it, I presented an analysis of the clinical development program for ...

Core Insights - Berger Montague PC is investigating claims against Novo Nordisk A/S under federal securities laws following a class action lawsuit filed against the company [1][2]. Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2].

Group 1 - Kenvue, the maker of Tylenol, is facing backlash due to unsupported claims linking its product to autism, which may lead to further scrutiny of other medications [1] - Robert F. Kennedy Jr. is leveraging his position to push unverified health claims into public policy, impacting access to various medications [1][2] - Kennedy's "Make America Healthy Again" initiative targets multiple drugs, including antidepressants and statins, raising concerns about their safety and necessity [3][4] Group 2 - The initiative aims to assess the risks associated with selective serotonin reuptake inhibitors, which are used by approximately 11% of the population for mental health issues [3] - Statins, prescribed to over 92 million Americans, are also under scrutiny despite evidence supporting their safety and effectiveness in preventing heart disease [4] - Kennedy's organization has published articles questioning the efficacy of cholesterol-related treatments, suggesting they are overprescribed [5] Group 3 - Newer diabetes and obesity treatments, such as GLP-1s, are also being criticized by Kennedy, who has made false claims about their marketing and effectiveness [6][7] - A proposal to have Medicare cover GLP-1 drugs for obesity was rejected, potentially limiting access for 7 million Americans [8] - Kennedy's rhetoric suggests a broader agenda against pharmaceutical companies and their products, raising concerns about future restrictions on various medications [1][8]

Core Insights - Eli Lilly's orforglipron shows superiority in lowering A1C levels compared to Novo Nordisk's oral semaglutide in a head-to-head trial for type 2 diabetes treatment [2][3] - The reported weight loss results for orforglipron may not be directly comparable to those of oral semaglutide due to differences in dosage used in trials [4][6] - The trial results should not be interpreted as a definitive victory for Eli Lilly in the obesity treatment market, which remains a more lucrative segment [7] Eli Lilly's Trial Data - The head-to-head trial aimed at reducing A1C levels, with orforglipron achieving a 2.2% reduction at 36mg compared to a 1.4% reduction for oral semaglutide at 14mg [3] - Eli Lilly reported an average weight loss of 9.2% with orforglipron at the highest dosage, while oral semaglutide at 14mg resulted in a 5.3% reduction [4] - Novo Nordisk is testing oral semaglutide at a higher dosage of 25mg, which has shown an average weight reduction of 16.6% in its trials [6] Implications for Investors - The positive trial results for Eli Lilly in type 2 diabetes treatment do not necessarily indicate that orforglipron will outperform oral semaglutide in the obesity indication, which is a more profitable market [7]

Core Insights - The article highlights three undervalued stocks: Novo Nordisk, Target, and Pfizer, which are trading below $100 per share and have strong fundamentals despite recent poor performance [2]. Novo Nordisk - Novo Nordisk is a major player in the GLP-1 drug market, with key products like Wegovy and Ozempic generating billions in revenue [4]. - The stock price has dropped nearly 32% this year, trading at just under $59, following a lowered fiscal year guidance due to slower growth and competition from knockoff drugs [5][6]. - Despite the recent downturn, the company has significant growth potential, particularly with Wegovy's expansion into new markets and promising results from its oral version [6][7]. Target - Target's stock has decreased almost 35% this year, currently trading around $88, with revenue for the first half of the year totaling $49.1 billion, down 2% year-over-year [9]. - The company faces challenges due to reduced consumer discretionary spending and economic conditions, but it aims to increase sales by $15 billion by the end of the decade through online marketplace growth and same-day delivery [10][11]. - Target generated nearly $3 billion in free cash flow over the past 12 months and trades at a low P/E multiple of slightly over 10, indicating it may be an undervalued stock worth considering [11]. Pfizer - Pfizer's stock is trading just over $24, down 9% since January and more than 50% from its 2021 highs, primarily due to concerns over future growth and multiple patent cliffs [12][13]. - Revenue for the first half of 2025 has only risen by 1% to $28.4 billion, raising concerns among growth investors [13]. - The company is expanding its pipeline through acquisitions, including a planned purchase of GLP-1 drugmaker Metsera for up to $7.3 billion, which could enhance its position in the obesity market [14][15]. - Pfizer generates substantial free cash flow of $12.4 billion over the past 12 months, providing financial flexibility for acquisitions and potential growth opportunities [15][16].

欧洲制药股在早盘交易中下跌，诺和诺德、诺华制药、阿斯利康在德国Tradegate交易平台下跌 1.7%-2%。 （文章来源：第一财经） ...

每经AI快讯，9月26日，诺和诺德在Tradegate交易平台上下跌3%。 ...

Core Insights - Amylin, a previously overlooked target, is emerging as a significant player in the multi-billion dollar weight loss market, particularly with the recent data from Novo Nordisk's cagrilintide and its combination with semaglutide showing promising weight loss results [1][2][3] Group 1: Clinical Developments - Novo Nordisk's cagrilintide achieved an average weight loss of 11.8% after 68 weeks of treatment in the REDEFINE 1 study [1] - The combination formulation CagriSema, which includes cagrilintide and semaglutide, demonstrated an average weight loss of 20.4%, significantly outperforming monotherapy [1][9] - Novo Nordisk has registered a Phase 2 clinical trial for NNC0662-0419, a GLP-1/GIP/Amylin triple agonist [1] Group 2: Industry Movements - Pfizer announced a $4.9 billion cash acquisition of Metsera to strengthen its weight loss pipeline, leading to a significant surge in Metsera's stock price [1] - Major pharmaceutical companies like Roche, AstraZeneca, Eli Lilly, and AbbVie are increasingly investing in Amylin through collaborations and acquisitions [2][11] Group 3: Mechanism and Competitive Advantage - Amylin is not a new target; it was discovered in 1987 but faced challenges in earlier formulations due to short half-lives and side effects [3][4] - New generation Amylin analogs have significantly improved half-lives, allowing for less frequent dosing, which enhances patient compliance [5][10] - Amylin's mechanism offers complementary effects to GLP-1, potentially leading to better patient outcomes through combined therapies [8][9] Group 4: Future Directions - The industry consensus is shifting towards collaborative strategies rather than isolated competition, with companies exploring combinations of Amylin and GLP-1 for enhanced efficacy [12][16] - Innovations in drug delivery systems, such as long-acting formulations and oral delivery methods, are being prioritized to improve patient adherence and treatment outcomes [15][16]

Market Movements - Oracle shares fell over 5% while Tesla dropped more than 4%, resulting in a market value loss of $64.5 billion (approximately 460.2 billion RMB) in one night [1] - Intel surged nearly 9% as it engaged in discussions with Apple regarding potential investments to strengthen its business foundation [3] - Cryptocurrency and weight-loss stocks saw significant declines, with Hut 8 down over 7% and Circle down over 5% [5] Economic Indicators - The U.S. GDP for Q2 was revised to an annualized quarter-on-quarter growth of 3.8%, exceeding expectations of 3.3% [8] - The core Personal Consumption Expenditures (PCE) price index for Q2 was reported at 2.6%, higher than the anticipated 2.5% [8] - Analysts noted that the strong GDP report indicates persistent inflation pressures, which may limit the Federal Reserve's future rate cuts [9] Federal Reserve Outlook - The Federal Reserve's recent rate cut of 25 basis points may not significantly alter its expected path for future cuts due to ongoing inflation concerns [9] - The probability of maintaining rates in October is 14.5%, while the likelihood of a 25 basis point cut is 85.5% [10]

Core Viewpoint - Novo Nordisk A/S is facing a class action lawsuit due to a significant reduction in its fiscal year 2025 guidance, which has led to a substantial drop in its stock price and alleged misleading statements made by the company during the class period [2][3][4]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk revised its fiscal year 2025 guidance, lowering sales growth expectations from 13-21% to 8-14% and operating profit from 16-24% to 10-16% [2]. - The company cited lower growth expectations for its products Ozempic and Wegovy, attributing this to market expansion slowdowns, increased competition, and ongoing use of compounded GLP-1s [2]. Group 2: Stock Impact - Following the announcement of the revised guidance, Novo Nordisk's stock price fell by $15.06, or 21.8%, closing at $53.94 per share on July 29, 2025 [3]. Group 3: Legal Action - The class action lawsuit alleges that during the class period, Novo Nordisk made materially false and misleading statements and failed to disclose adverse facts about its business and prospects [4]. - Specific allegations include the company's failure to recognize the significance of the personalization exception for GLP-1 compounding and overestimating its ability to attract patients transitioning from compounded treatments [4]. - Investors who purchased Novo Nordisk securities during the class period have until September 30, 2025, to file a lead plaintiff motion in the lawsuit [5].